Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
88591 trials found · Page 114 of 4430
-
Early malaria screening may prevent stillbirth and low birth weight
Prevention Recruiting nowThe purpose of the INTREPiD study is to compare 1st trimester screening for malaria parasites with a high-sensitivity malaria rapid diagnostic test followed by treatment of test-positive women with artemether-lumefantrine (AL) against usual antenatal care on a composite adverse p…
Phase: PHASE4 • Sponsor: Duke University • Aim: Prevention
Last updated Apr 26, 2026 20:00 UTC
-
New drug combo shows promise for rare eye cancer that spreads
Disease control OngoingThis is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ip…
Phase: PHASE2, PHASE3 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
Could some breast cancer patients skip chemo? major trial seeks answers
Disease control Recruiting nowThis Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EB…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC
-
Targeted alpha rays take aim at Hard-to-Treat tumors
Disease control Recruiting nowThis study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Phase: PHASE1, PHASE2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated Apr 24, 2026 16:18 UTC
-
New hope for rare cancer: drug duo aims to slow tumor growth
Disease control Recruiting nowThe primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compare…
Phase: PHASE3 • Sponsor: PharmaMar • Aim: Disease control
Last updated May 01, 2026 12:14 UTC
-
New TB tests could save millions by catching cases faster
Diagnosis Recruiting nowEvery year, more than 3 million people with TB remain undiagnosed and 1 million die. Better diagnostics are essential to reducing the enormous burden of TB worldwide. The Assessing Diagnostics At Point-of-care for Tuberculosis (ADAPT) study seeks to reduce the burden of TB worldw…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated May 01, 2026 12:14 UTC
-
New drug trial aims to restore movement after spinal cord injury
Disease control Recruiting nowA Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects
Phase: PHASE1, PHASE2 • Sponsor: NervGen Pharma • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New drug combo shows promise in advanced lung cancer trial
Disease control OngoingThis study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs". 'Investigational' means that the study drug is not app…
Phase: PHASE2, PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 01, 2026 12:13 UTC
-
New combo therapy aims to boost lung cancer survival
Disease control OngoingThis study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced…
Phase: PHASE2, PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 26, 2026 20:03 UTC
-
New hope for lung cancer patients whose targeted treatment has failed
Disease control OngoingThis is a randomized, open-label, multicenter Phase 3 clinical study to evaluate SKB264 monotherapy versus pemetrexed in combination with platinum in subjects with locally advanced or metastatic non-squamous NSCLC with EGFR mutation who have failed to EGFR-TKI therapy.
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC
-
New Alpha-Particle therapy targets tough melanoma
Disease control Recruiting nowIn this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectab…
Phase: PHASE1, PHASE2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC
-
Combination therapy may improve outcomes in Late-Window stroke
Disease control CompletedTo assess the effect of intravenous tenecteplase plus endovascular thrombectomy (EVT) compared to EVT alone on 4.5 to 24 hours after stroke due to basilar artery occlusion.
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of University of Science and Technology of China • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
Promising new radiation drug targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis is a prospective, open-label, dose-escalation and randomized dose optimization and expansion study. The Phase Ib portion of the study aims to determine the safety and tolerability of escalating doses of \[212Pb\]Pb-ADVC001 administered every 6, 4, 2 or 1 week(s) and establis…
Phase: PHASE1, PHASE2 • Sponsor: AdvanCell Pty Limited • Aim: Disease control
Last updated Apr 24, 2026 16:07 UTC
-
Breast cancer drugs take on rare tumors in new trial
Disease control Recruiting nowThis clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other anti-cancer drugs). This means it has gone through clin…
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC
-
New chemo cocktail aims to extend life in advanced stomach cancer
Disease control Recruiting nowThis phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esopha…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Apr 24, 2026 16:20 UTC
-
New combo therapy shows promise for hard-to-treat liver cancer
Disease control CompletedThis study is investigator initiated, single-institution, prospective, phase 2 open-label study to determine the efficacy and safety of combination therapy of atezolizumab/bevacizumab and proton beam therapy to portal vein tumor thrombosis with or without main primary tumor in pa…
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC
-
New bladder cancer drug could help patients avoid bladder removal
Disease control Recruiting nowThis is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to…
Phase: PHASE3 • Sponsor: Fidia Farmaceutici s.p.a. • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Immunotherapy drug shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingIn this study, the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancer will be assessed.
Phase: PHASE2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
Fast MRI boosts early liver cancer detection in High-Risk patients
Diagnosis Recruiting nowIntro: Hepatocellular carcinoma (HCC) is the 6th leading cause of cancer worldwide. In France, more than 10,000 new cases are identified each year. The latter occur in 85% of cases in cirrhosis, the most frequent causes of which are excessive alcohol consumption, metabolic syndro…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated May 01, 2026 12:26 UTC
-
Promising targeted therapy for tough brain tumors moves forward
Disease control Recruiting nowThis study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks…
Phase: PHASE1, PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated May 01, 2026 12:14 UTC